Analysts at StockNews.com started coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research report issued on Sunday. The firm set a "sell" rating on the biotechnology company's stock.
Separately, BTIG Research cut shares of OncoSec Medical from a "buy" rating to a "neutral" rating in a report on Monday, November 14th.
Get OncoSec Medical alerts:OncoSec Medical Price Performance
Shares of NASDAQ:ONCS opened at $1.96 on Friday. The company's 50 day moving average is $5.34 and its two-hundred day moving average is $11.08. OncoSec Medical has a 52 week low of $1.50 and a 52 week high of $31.90.
Institutional Inflows and Outflows
An institutional investor recently raised its position in OncoSec Medical stock. Renaissance Technologies LLC increased its holdings in shares of OncoSec Medical Incorporated (NASDAQ:ONCS – Get Rating) by 48.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 72,898 shares of the biotechnology company's stock after purchasing an additional 23,900 shares during the period. Renaissance Technologies LLC owned 0.19% of OncoSec Medical worth $54,000 as of its most recent SEC filing.OncoSec Medical Company Profile
(Get Rating)
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.
Featured Stories
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.